Bristol Takes $1.8B Hit, Ditches Hepatitis C Drug After Death
By Jeff Overley ( August 24, 2012, 8:09 PM EDT) -- Bristol-Myers Squibb Co. on Friday said it's taking a $1.8 billion charge because of the previous day's abandonment of its hepatitis C treatment that was linked to severe side effects after being acquired in a multibillion-dollar deal earlier this year....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.